A Phase 2 interventional study of 5mg/kg omalizumab injection and 15mg/kg omalizumab injection in Allergies and Food Allergy, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 1 Year to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.
Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 10th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 1–30
Johns Hopkins University · Sites in United States
Ages 1–55
National Jewish Health · Sites in United States
Ages 1–55 · Healthy volunteers
By country, each count listing its studies:
Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.
This study: 1 Year to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, omalizumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 4 5
First in 2009; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 30 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 34 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 4 studies filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
2 of the studies testing omalizumab in Food Hypersensitivity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06934200Johns Hopkins UniversityOmalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels | 2027-04-15 |
| NCT06943534Massachusetts General HospitalOmalizumab Weight-Based Dosing Efficacy Trial | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing omalizumab in Food Hypersensitivity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
This research is being conducted to assess the safety and effectiveness of omalizumab for food allergies dosed differently from what is currently FDA approved. The study hypothesizes the current way of dosing omalizumab may not work well for all patients with food allergy and it unnecessarily excludes some individuals with very high allergic antibody (IgE) who may benefit. This study will include subjects regardless of IgE level. One of the goals is to learn more about how safe and effective Omalizumab is for people with these high IgE levels, since this has not been fully studied before.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Browse Food Hypersensitivity studies →Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Compared within Food Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(If meeting above criteria):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will receive a does of 5mg/kg Omalizumab per month divided every two (2) weeks for 16 weeks.
Drug: 5mg/kg omalizumab injection
Participants randomized to this arm will receive a does of 15mg/kg Omalizumab per month divided every two (2) weeks for 16 weeks.
Drug: 15mg/kg omalizumab injection
Drug page: OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
5mg/kg of omalizumab
Also known as: Xolair
Drug page: OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
15mg/kg of omalizumab
Also known as: Xolair
Proportion of participants that tolerate the 600 mg dose after treatment.
The primary analysis of outcome is on the proportion of subjects tolerating at least 600 mg at the post-treatment OFC in either group against the expected outcome without treatment based on OUTMATCH data.
Time frame: 16 Weeks
Other measures of omalizumab treatment effect on food allergy
Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate a single dose 1000 mg allergen
Time frame: 16 Weeks
Other measures of omalizumab treatment effect on food allergy
Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate a single dose 2000 mg allergen
Time frame: 16 Weeks
Other measures of omalizumab treatment effect on food allergy
Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● The proportion of participants that tolerate two doses of 2000 mg allergen
Time frame: 16 Weeks
Other measures of omalizumab treatment effect on food allergy
Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment: ● Reaction severity of positive post treatment reactions using the CoFAR grading scale ranging from 1 (mild) to 5 (death)
Time frame: 16 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.
Of 19 phase 2 interventional studies under Food Hypersensitivity, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omalizumab
Massachusetts General Hospital →